Edition:
United States

Baxter International Inc (BAX)

BAX on New York Consolidated

44.84USD
9 Dec 2016
Change (% chg)

$0.76 (+1.72%)
Prev Close
$44.08
Open
$44.21
Day's High
$44.87
Day's Low
$44.09
Volume
2,493,568
Avg. Vol
4,192,760
52-wk High
$50.16
52-wk Low
$34.06

Select another date:

Tue, Nov 22 2016

BRIEF-Baxter presented exploratory research on the removal of inflammation-related molecules during extracorporeal blood purification therapy

* Baxter International Inc - presented exploratory research on the removal of inflammation-related molecules during extracorporeal blood purification therapy

BRIEF-Baxter declares quarterly dividend and announces expanded share repurchase authorization

* Baxter declares quarterly dividend and announces expanded share repurchase authorization

BRIEF-Baxter Q3 adj earnings per share $0.56 from continuing operations excluding items

* Baxter reports third quarter 2016 results and increases financial outlook for full-year 2016

Fitch Affirms Baxter International Inc.'s IDR at 'BBB+'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, October 03 (Fitch) Fitch Ratings has affirmed Baxter International Inc.'s (BAX/Baxter) Long-Term Issuer Default Rating at 'BBB+'. The Rating Outlook is Stable. Baxter had approximately $3.2 billion in outstanding debt at June 30, 2016. A full list of Baxter's ratings follows at the end of this release. KEY RATING DRIVERS --The 'BBB+' rating reflects Baxter's significant deleveraging and strong operating performance post th

Fitch Rates Baxter International Inc.'s Notes Offering 'BBB+'

(The following statement was released by the rating agency) CHICAGO, August 10 (Fitch) Fitch Ratings has assigned a 'BBB+' rating to Baxter International Inc.'s (Baxter) senior unsecured notes offering. Fitch expects the net proceeds from the issuance to be used to pay down existing debt and short-term borrowings, as well as other general corporate purposes. Baxter had approximately $3.2 billion in outstanding debt at June 30, 2016. A full list of Baxter's ratings follows at the end of this

BRIEF-Sunshine Heart buys Baxter's Aquadex product line

* Sunshine Heart announces strategic acquisition of Aquadex product line from Baxter and a new credit facility with Silicon Valley Bank

BRIEF-Baxter presents results of study related to REVACLEAR dialyzer

* Baxter presents new evidence demonstrating REVACLEAR Dialyzer associated with lower drug use during hemodialysis

BRIEF-Baxter Q2 earnings $2.19/shr from cont ops

July 26 Baxter Reports Second Quarter 2016 Results And Raises Financial Outlook For Full

BRIEF-Baxter International sets quarterly dividend of $0.13 per share

* Sets quarterly dividend of $0.13 per share Source text for Eikon: Further company coverage:

BRIEF-Co Don says Bauerfeind AG is new major shareholder

* Bauerfeind AG indirectly holds a blocking minority of 25 pct of the shares in Co.Don AG Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: